Welcome to our dedicated page for Core Scientific, Inc./tx SEC filings (Ticker: CORZZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Core Scientific, Inc./tx's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Core Scientific, Inc./tx's regulatory disclosures and financial reporting.
Core Scientific reported a large headline net loss driven primarily by non-cash changes in derivative valuations, while its operating business shows mixed trends. Cash and cash equivalents declined to $581.3 million from $836.2 million, but the company materially increased its bitcoin holdings to 1,612 BTC with a fair value of $172.8 million. Total assets rose to $1.978 billion and property, plant and equipment, net increased to $828.6 million, reflecting ongoing capital investment.
Revenue fell versus prior year to $78.6 million for the quarter, producing a small gross profit but operating losses as selling, general and administrative costs rose. Large non-operating items included a $923.5 million increase in the fair value of Tranche 2 warrants recorded as expense, producing a three-month net loss of $936.8 million. Warrant liabilities total $1.3167 billion, convertible debt remains significant, and contractual capital commitments total approximately $1.71 billion. The company disclosed the proposed acquisition by CoreWeave and detailed related transaction risks.
Core Scientific, Inc. furnished a press release announcing its financial results for the second fiscal quarter ended June 30, 2025. The press release is provided as Exhibit 99.1 to this Current Report and is incorporated by reference into Items 2.02 and 7.01 of the filing. The company states that the information in Items 2.02 and 7.01, including Exhibit 99.1, is furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, nor incorporated by reference in Securities Act filings.
The 8-K itself does not include the underlying financial metrics or operational detail; readers must review Exhibit 99.1 for the actual results. The filing also lists the registrant's exchange-listed securities: common stock CORZ and warrants CORZW and CORZZ.
Two Seas Capital LP, together with its general partner and CIO Sina Toussi, filed a Schedule 13D disclosing beneficial ownership of 19,122,842 Core Scientific (CORZZ) shares, or 6.3 % of the outstanding common stock. The position is held across the firm’s Strategic Fund, Global Fund and two managed accounts and includes 5.72 m options and 313.6 k warrants. Aggregate consideration for the shares, options and warrants totals roughly $133.9 million, funded with the working capital of the funds/accounts.
The filing signals an activist stance: on 7 Aug 2025 Two Seas issued an open letter stating it will vote against the proposed merger between Core Scientific and CoreWeave and intends to solicit proxies opposing the deal at the forthcoming special meeting. The filer may engage management and other shareholders, and could adjust its exposure through additional purchases, sales or hedging transactions—including swaps that reference a notional 500 k shares—depending on market conditions and strategic considerations.